Recent Activity
January — Issue #1
Evidence Showdown
When Clinical Benefit Emerges in ACS Patients Treated with DynamX versus Resolute Onyx
Clinical benefit emerges precisely when DynamX unlocks at six months—trial data shows 48% risk reduction through two years in acute coronary syndrome patients.
Case Reasoning
Dual Anticoagulant Delivery Targets the First 72 Hours When ACS Patients Face Peak Thrombotic Risk
Trial data shows how targeted anticoagulant delivery during peak thrombotic vulnerability translates to zero early complications versus 5% in controls—preventing heart attacks when ACS patients face greatest risk.
Technology Explained